PROSPECTs Futile For Bavarian Nordic's Prostvac Cancer Vaccine
The Phase III PROSPECT study's data monitoring committee decides against continuing after interim analysis. The fall-out could hit Bavarian Nordic’s CV301 too.
The Phase III PROSPECT study's data monitoring committee decides against continuing after interim analysis. The fall-out could hit Bavarian Nordic’s CV301 too.